| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -21.2 | -17.7 |
| Net income | -21.2 | -17.7 |
| EPS (diluted, $ a share) | $-0.23 | $-0.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: WHWK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Whitehawk Therapeutics, Inc.: key numbers
- Share price
- $3.01Close, Nov 16
- Market cap
- $178M
- Shares outstanding
- 59.01MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Whitehawk Therapeutics, Inc.
All →Whitehawk Therapeutics Financial Results
Whitehawk Therapeutics reported third quarter 2026 financial results, ending the period with $169.7 million in cash which is expected to fund operations into the second half of 2028. The company highlighted the initiation of its Phase 1 trial for HWK-206 and remains on track to report initial data from its HWK-007 and HWK-016 programs in the first half of 2027.
“We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027. We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months.”
Dave Lennon, PhD, President and Chief Executive Officer